| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Revenue | 0 | 0 | 2 | |
| Research and development | 469 | 185 | 347 | |
| General and administrative | 718 | 854 | 747 | |
| Total operating expenses | 1,187 | 1,039 | 1,094 | |
| Loss from operations | -1,187 | -1,039 | -1,092 | |
| Change in fair value of warrant liability | 0 | 31 | - | |
| Other income, net | 28 | 19 | 19 | |
| Other income (expense), net | 28 | -12 | 19 | |
| Net loss | -1,159 | -1,051 | -1,073 | |
| Earnings per share, basic, total | -0.55 | -0.63 | -0.67 | |
| Earnings per share, diluted, total | -0.55 | -0.63 | -0.67 | |
| Weighted average number of shares outstanding, basic, total | 2,183,039 | 1,676,345 | 1,601,252 | |
| Weighted average number of shares outstanding, diluted, total | 2,183,039 | 1,676,345 | 1,601,252 | |
Alaunos Therapeutics, Inc. (TCRT)
Alaunos Therapeutics, Inc. (TCRT)